| Literature DB >> 30063105 |
Andrew M Piacitelli1, Dana M Jensen2, Heather Brandling-Bennett3, Megan Mariner Gray4, Maneesh Batra4, Juliane Gust1,5, Ameet Thaker6, Catherine Paschal7,8, Karen Tsuchiya7,8, Colin C Pritchard8, Jonathan Perkins9, Ghayda M Mirzaa1,10, James T Bennett2,10.
Abstract
PIK3CA-related overgrowth spectrum (PROS) refers to a group of disorders of segmental overgrowth of a wide variety of tissues as well as venous and lymphatic malformations. Clinical and molecular diagnosis can be challenging due to phenotypic heterogeneity and difficulties detecting low-level mosaicism using standard methods. Here, we report a patient with a severe presentation of PIK3CA-related overgrowth with analysis of 27 posthumously collected tissues by droplet digital polymerase chain reaction (PCR) at autopsy. This patient had a complicated medical course, with coagulopathy, ischemic brain injury, and sepsis resulting in multi-organ failure and death at age 2 months despite sirolimus therapy. Five of the 27 tissues analyzed possessed a mosaic PIK3CA mutation (p.E545K), with mutation levels ranging from 3 to 20% across affected tissues. We found no correlation between tissue-specific disease severity and mutation levels, likely reflecting sampling limitations. We also tested a series of 22 individuals with somatic overgrowth and/or vascular-lymphatic malformations using a targeted next generation sequencing panel and found PIK3CA mutations in nine individuals, identifying three novel PIK3CA variants. This report expands the clinical and molecular spectrum of PROS, emphasizes that different molecular methods can be complimentary in the diagnosis of these disorders, and highlights the risk of coagulopathy in a subset of patients with PIK3CA-related overgrowth.Entities:
Keywords: zzm321990PIK3CA; ddPCR; mosaicism; overgrowth; vascular malformation
Mesh:
Substances:
Year: 2018 PMID: 30063105 PMCID: PMC6290925 DOI: 10.1002/ajmg.a.40487
Source DB: PubMed Journal: Am J Med Genet A ISSN: 1552-4825 Impact factor: 2.802